- Home
- LFST vs TARS Comparison
LFST vs TARS Comparison
Compare LFST & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFST | TARS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LFST | TARS |
|---|---|---|
| Price | $7.07 | $68.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $8.83 | ★ $77.13 |
| AVG Volume (30 Days) | ★ 1.5M | 628.1K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,367,570,000.00 | $366,100,000.00 |
| Revenue This Year | $15.75 | $147.71 |
| Revenue Next Year | $14.36 | $53.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.39 | ★ 182.44 |
| 52 Week Low | $3.74 | $38.51 |
| 52 Week High | $8.30 | $85.25 |
Technical Indicators
Market Signals| Indicator | LFST | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 20.56 |
| Support Level | $7.02 | $69.46 |
| Resistance Level | $7.37 | $73.82 |
| Average True Range (ATR) | 0.23 | 2.80 |
| MACD | -0.05 | -1.00 |
| Stochastic Oscillator | 15.00 | 0.00 |
Price Performance
Historical ComparisonAbout LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.